Light Chain Deposition Disease in an Older Adult Patient Successfully Treated with Long-term Administration of Bortezomib, Melphalan and Prednisone

被引：2

作者：

Hiyamuta, Hiroto ^{[1
]}

Yamada, Shunsuke ^{[1
]}

Matsukuma, Yuta ^{[1
]}

Tsuchimoto, Akihiro ^{[1
]}

Nakano, Toshiaki ^{[1
]}

Taniguchi, Masatomo ^{[1
]}

Masutani, Kosuke ^{[1
]}

Yoshimoto, Goichi ^{[2
]}

Muta, Tsuyoshi ^{[3
]}

Akashi, Koichi ^{[2
]}

Kitazono, Takanari ^{[1
]}

Tsuruya, Kazuhiko ^{[1
,4
]}

机构：

[1] Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka 812, Japan

[2] Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Fukuoka 812, Japan

[3] Japan Community Hlth Care Org Kyushu Hosp, Dept Hematol Oncol, Niigata, Japan

[4] Kyushu Univ, Grad Sch Med Sci, Dept Integrated Therapy Chron Kidney Dis, Fukuoka 812, Japan

来源：

INTERNAL MEDICINE | 2016年 / 55卷 / 10期

关键词：

cardiac involvement; liver involvement; multiple myeloma; ocular involvement; VMP therapy; STEM-CELL TRANSPLANTATION; MULTIPLE-MYELOMA; RENAL INVOLVEMENT; FAILURE; LIVER; CHEMOTHERAPY; DISORDERS;

D O I：

10.2169/internalmedicine.55.5752

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 70-year-old woman was admitted to our hospital because of fatigue and renal dysfunction and was diagnosed with light chain deposition disease (LCDD) with multiple organ involvement (kidney, thyroid gland, heart and eyes). After chemotherapy with bortezomib, cyclophosphamide and dexamethasone, hepatobiliary enzyme levels increased abruptly. A liver biopsy showed light chain deposition in Disse spaces. After two years of treatment with bortezomib, melphalan and prednisone (VMP) administered at shorter intervals relative to regular cycles, the patient showed a hematological and organ response. This case indicates that a relatively low dose intensity VMP regimen is preferable for elderly patients with LCDD with multiple organ involvement.

引用

页码：1319 / 1325

页数：7

共 19 条

[1] MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE - LIGHT CHAIN AND LIGHT AND HEAVY-CHAIN DEPOSITION DISEASES AND THEIR RELATION TO LIGHT CHAIN AMYLOIDOSIS - CLINICAL-FEATURES, IMMUNOPATHOLOGY, AND MOLECULAR ANALYSIS
BUXBAUM, JN
CHUBA, JV
HELLMAN, GC
SOLOMON, A
GALLO, GR
[J]. ANNALS OF INTERNAL MEDICINE, 1990, 112 (06) : 455 - 464
[2] Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study
Chanan-Khan, Asher A.
Kaufman, Jonathan L.
Mehta, Jayesh
Richardson, Paul G.
Miller, Kena C.
Lonial, Sagar
Munshi, Nikhil C.
Schlossman, Robert
Tariman, Joseph
Singhal, Seema
[J]. BLOOD, 2007, 109 (06) : 2604 - 2606
[3] Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure
Gharwan, Helen
Truica, Cristina I.
[J]. MEDICAL ONCOLOGY, 2012, 29 (02) : 1197 - 1201
[4] NF-κB as a therapeutic target in multiple myeloma
Hideshima, T
Chauhan, D
Richardson, P
Mitsiades, C
Mitsiades, N
Hayashi, T
Munshi, N
Dang, L
Castro, A
Palombella, V
Adams, J
Anderson, KC
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (19) : 16639 - 16647
[5] Light chain deposition disease: novel biological insights and treatment advances
Jimenez-Zepeda, V. H.
[J]. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2012, 34 (04) : 347 - 355
[6] Treatment of light chain deposition disease with bortezomib and dexamethasone
Kastritis, Efstathios
Migkou, Magdalini
Gavriatopoulou, Maria
Zirogiannis, Panos
Hadjikonstantinou, Valsamakis
Dimopoulos, Meletios A.
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (02): : 300 - 302
[7] Long-term outcome of autologous stem cell transplantation in light chain deposition disease
Lorenz, Elizabeth C.
Gertz, Morie A.
Fervenza, Fernando C.
Dispenzieri, Angela
Lacy, Martha Q.
Hayman, Suzanne R.
Gastineau, Dennis A.
Leung, Nelson
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (06) : 2052 - 2057
[8] Light chain deposition disease of the liver without renal involvement in a patient with multiple myeloma related to liver failure and rapid fatal outcome
Michopoulos, S
Petraki, K
Petraki, C
Dimopoulos, MA
[J]. DIGESTIVE DISEASES AND SCIENCES, 2002, 47 (04) : 730 - 734
[9] Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement
Minarik, Jiri
Scudla, Vlastimil
Tichy, Tomas
Pika, Tomas
Bacovsky, Jaroslav
Lochman, Pavel
Zadrazil, Josef
[J]. LEUKEMIA & LYMPHOMA, 2012, 53 (02) : 330 - 331
[10] The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
Mitsiades, N
Mitsiades, CS
Richardson, PG
Poulaki, V
Tai, YT
Chauhan, D
Fanourakis, G
Gu, XS
Bailey, C
Joseph, M
Libermann, TA
Schlossman, R
Munshi, NC
Hideshima, T
Anderson, KC
[J]. BLOOD, 2003, 101 (06) : 2377 - 2380

← 1 2 →